A phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered asmonotherapy and in combination with cetrelimab and radiotherapy for advanced nonsmallcell lung cancer

The purpose of this study is to find out if JNJ-86974680 taken by itself or together with Cetrelimab and radiotherapy can cause side effects which are unexpected or unwanted reactions. This is the first time that JNJ-86974680 is being used in people. Radiotherapy is also part of the study treatment and not part of your standard of care. JNJ-86974680 and Cetrelimab are experimental drugs and not approved by the Food and Drug Administration (FDA). JJNJ-86974680 is a small molecule that may block adenosine function. Adenosine is a chemical in the body that can reduce the ability of your immune cells to kill cancer. High levels of adenosine can be present in cancers, and blocking adenosine can increase the ability of your immune cells to kill cancer cells. Cetrelimab is an antibody that blocks the programmed death-1 (PD-1) protein. Antibody is a protein produced by the body's immune system when it detects harmful substances. Both PD-1 and adenosine are present in cancers and are known to lower the ability of your immune system to kill cancer cells. Blocking PD-1 and adenosine may increase the ability of your immune system to kill your cancer cells, especially if given together with radiotherapy. A key purpose of this study is to find a dose of JNJ-86974680 that effectively blocks adenosine and that is safe and effective to use for treatment of non-small cell lung cancer when taken together with Cetrelimab and radiotherapy.

Are you Eligible? (Inclusion Criteria)

• Must be 18 years old or older - Cannot be pregnant, breastfeed, plan to become pregnant, or father a child while enrolled in this study and within 6 months after last dose - No major surgery within 4 weeks before the first dose of study treatment